Global Pravastatin Market Research Report 2021

Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used in combination with diet, exercise, and weight loss for lowering cholesterol and preventing cardiovascular disease.

The global Pravastatin market was valued at US$ XX million in 2020 and is expected to reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
This report focuses on Pravastatin volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Pravastatin market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Pravastatin Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
10mg Tablet
20mg Tablet
40mg Tablet
80mg Tablet

Segment by Application
Adults
Children

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Bristol-Myers Squibb
TEVA
SANDOZ
APOTEX
Dr. Reddy's Laboratories
Zydus Pharmaceuticals
Cipla Inc.
Lupin Pharmaceuticals
Glenmark
Mylan
Aurobindo Pharma
Accord Healthcare
Upsher-Smith Laboratories
Hisun
Jiangxi Boyaseehot Pharmaceutical
Shanghai Shyndec Pharmaceutical
Daiichi Sankyo
North China Pharmaceutical Group